---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-202610"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:04:47.210348+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kyverna Therapeutics appoints Nadia Dac as CCO; leads commercial launch for miv-cel in stiff person syndrome

## Summary
- Nadia Dac appointed Chief Commercial Officer effective May 4, 2026; has 30+ years experience in neurology and rare disease launches.
- She will lead commercial strategy for miv-cel (KYV-101), which is poised for first approval in stiff person syndrome with neuroimmunology expansion.
- Previously CCO at Omeros (launched Yartemlea) and Alder (launched Vyepti); held leadership roles at AbbVie, Novartis, Biogen.
- Received inducement option for 300,000 shares vesting over 4 years (25% after 1 year, monthly thereafter); exercise at May 4 closing price.

## SEC filing metadata
- accession: 0001193125-26-202610
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/0001193125-26-202610-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/kytx-20260415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-202610
- JSON: https://secwatch.observer/filing/0001193125-26-202610.json
- Plain text: https://secwatch.observer/filing/0001193125-26-202610.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.